Dilaforette AB Announces the Appointment of Christina Herder
News Jan 22, 2014
Dilaforette AB has announced the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry.
“We are delighted that Christina is joining Dilaforette. Her expertise and experience will help us take the company forward to successful outcomes in malaria and sickle cell disease. I look forward to working with her over the next years”, says Robin Wright, Chairman of Dilaforette.
Dilaforette is developing sevuparin, a proprietary polysaccharide-based drug, for treatment of hematological crisis in malaria as well as vaso-occlusive crisis in sickle cell disease.
“I am looking forward to lead Dilaforette and to develop sevuparin into new therapies for patients, with a large unmet medical need”, says Christina Herder.
Christina holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Christina Herder joins Dilaforette from Sobi, where she has been working within Corporate Development as well as previously heading up the Portfolio Management in R&D.
She brings over 20 years of experience from pharmaceutical product development from Pharmacia, Medicarb, Biovitrum and Sobi. She has also been board member of Akinion Pharmaceuticals AB, for five years.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019